Serina Therapeutics completes sentinel dosing in Phase 1b trial of Parkinson’s drug SER-252

Serina Therapeutics Inc

Serina Therapeutics Inc

SER

0.00
  • Serina Therapeutics completed sentinel dosing in Cohort 1 of its Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease.
  • An independent safety committee reviewed 72-hour safety data, recommended continued dosing in the remainder of Cohort 1.
  • Enrollment and dosing in Cohort 1 now expected to finish ahead of prior guidance for end of Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607091210PRIMZONEFULLFEED9759861) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.